A Study of ALX148 With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Myeloid Leukemia
- AML, Adult
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The Phase 1 will consist of a dose escalation of ALX148 in combination with venetoclax and azacitidine to evaluate safety and tolerability, and to identify the recommended Phase 2 dose of ALX148 in combination with venetoclax and azacitidine. The Phase 2 will evaluate the efficacy of ALX148 in combi...
The Phase 1 will consist of a dose escalation of ALX148 in combination with venetoclax and azacitidine to evaluate safety and tolerability, and to identify the recommended Phase 2 dose of ALX148 in combination with venetoclax and azacitidine. The Phase 2 will evaluate the efficacy of ALX148 in combination with venetoclax and azacitidine for patients with AML.
Tracking Information
- NCT #
- NCT04755244
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon